A double‐blind placebo‐controlled clinical trial of recombinant human brain‐derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
A randomized, double‐blind, placebo‐controlled study of brain‐derived neurotrophic factor (rhBDNF) was conducted in 30 patients with insulin‐treated diabetes mellitus, with obligatory abnormalities of sural nerve conduction studies and vibration perception threshold (VPT) at the great toe on recruitment. Nine patients received placebo, 11 rhBDNF (25 μg/kg) and 10 rhBDNF (100 μg/kg) s.c. daily for 3 months, and were assessed at days 0, 8, 15, 29, 43, 57 and 85 with nerve conduction and quantitative sensory and autonomic tests including VPT, thermal and light touch thresholds, and cutaneous axon‐reflexes. No statistically significant differences were found among the 3 treatment groups between baseline and day 85 values. To examine possible reasons for lack of effect, post hoc analysis was performed. In the subset of patients with abnormal but detectable cool detection threshold (CDT) at baseline, there was improvement of CDT at day 85 when compared to baseline in the treated (p < 0.02) but not placebo group. Further, from days 43 to 85, in the treated group but not the placebo group, CDT was indistinguishable from a group of matched normal subjects (p> 0.05). Skin biopsies failed to show evidence of structural change; assessment of innervation of hair follicles, which is partly dependent on BDNF, was not possible because of the marked loss of this end‐organ in diabetic neuropathic skin. The only side effects of rhBDNF were infrequent non‐painful injection‐site skin reactions and increased gut motility at the higher dose. We conclude that further preclinical studies are warranted before any future clinical trials to see if rhBDNF improves CDT and constipation in diabetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Purification of a new neurotrophic factor from mammalian brain.
Barde, Y. A., Edgar, D., & Thoenen, H. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01207.x · Cited by 1,822 · cited 1×
“Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, and acts via its highaffinity receptor, Trk B (Barde et al., 1982; Lindsay, 1993).”
BackgroundDisorders of gastrointestinal motility associated with diabetes mellitus
FELDMAN, M., & SCHILLER, L. R. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-3-378 · Cited by 653
Cited by
Boulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1458 · Cited by 913
NEUROTROPHINS: Mediators and Modulators of Pain
Pezet, S., & McMahon, S. B. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112929 · Cited by 879
Malik, R. A., Kallinikos, P., Abbott, C. A., van Schie, C. H. M., Morgan, P., Efron, N., & Boulton, A. J. M. (2003) · Diabetologia · doi:10.1007/s00125-003-1086-8 · Cited by 505
Thoenen, H., & Sendtner, M. (2002) · Nature Neuroscience · doi:10.1038/nn938 · Cited by 336
Longo, F. M., & Massa, S. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4024 · Cited by 298
Metadata
- Authors
- Wellmer, A., Misra, V. P., Sharief, M. K., Kopelman, P. G., & Anand, P.
- Venue
- Journal of the Peripheral Nervous System
- Publisher
- Wiley
- Published
- 2001-12
- Volume
- 6
- Issue
- 4
- Pages
- 204-210
- ISSN
- 1085-9489 (ISSN-L)
- 1529-8027
- OpenAlex
- W1985267787
- Cited by
- 111
- References
- 2
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double‐blind placebo‐controlled clinical trial of recombinant human brain‐derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. https://app.cochat.ai/papers/10.1046/j.1529-8027.2001.01019.x
- The paper
- Wellmer, A., Misra, V. P., Sharief, M. K., Kopelman, P. G., & Anand, P. (2001). A double‐blind placebo‐controlled clinical trial of recombinant human brain‐derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. Journal of the Peripheral Nervous System. https://doi.org/10.1046/j.1529-8027.2001.01019.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.